Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CT-01 + 5-FU in Metastatic Colorectal Cancer
NCT00110721Phase 2Terminated
- Sponsor
- Galectin Therapeutics
- Start
- May 2005
- Primary completion
- Jun 2007
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Davanat in metastatic colorectal cancer (mCRC), sponsored by Galectin Therapeutics. Primary endpoints: Frequency of objective complete or partial tumor response and Frequency of stable disease. Started May 2005; status: terminated.
02
Drugs
Davanat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00110721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110721.